The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease-Reference-Cited by-同舟云学术

The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease

Published:2014-11 Issue:6 Volume:8 Page:594-605
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Toth Peter P.,Thanassoulis George,Williams Ken,Furberg Curt D.,Sniderman Allan^ORCID

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference54 articles.

1. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;Circulation,2013

2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III);JAMA,2001

3. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS);Reiner;Eur Heart J,2011

4. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations;Genest;Can J Cardiol,2009

5. An International Atherosclerosis Society Position Paper;J Clin Lipidol,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey;Archives of Medical Science;2020

2. Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition;Current Diabetes Reports;2019-07-22

3. What is sufficient drug therapy for lipoprotein elevations?;Journal of Clinical Lipidology;2017-11

4. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol;Journal of the American Heart Association;2016-10-03

5. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease;Circulation;2016-04-19